Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Reich-Slotky R, Makhani SS, Vasovic LV, Pearse RN, Rossi A, Philips A, et al. Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. Leuk Lymphoma. 2018;59(12):2829-2835.

Ko H-, Berk M, Chung Y-, Willard B, Bareja R, Rubin M, et al. Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate Cancer. Cell Rep. 2018;22(3):809-819.

Schwartz Z, Bowe RB, Coleman M, Magro CM. Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity. Ann Diagn Pathol. 2018;37:57-61.

Magro CM, Kazi N, Sisinger AE. Primary cutaneous histiocytic sarcoma: A report of five cases with primary cutaneous involvement and review of the literature. Ann Diagn Pathol. 2018;32:56-62.

Correction: Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. Cancer Prev Res (Phila). 2018;11(4):249.

Huang J, Duran A, Reina-Campos M, Valencia T, Castilla EA, Müller TD, et al. Adipocyte p62/SQSTM1 Suppresses Tumorigenesis through Opposite Regulations of Metabolism in Adipose Tissue and Tumor. Cancer Cell. 2018;33(4):770-784.e6.

Simpkins F, Jang K, Yoon H, Hew KE, Kim M, Azzam DJ, et al. Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells. Clin Cancer Res. 2018;24(19):4874-4886.

J Mulvey J, Magro C, Chadburn A. Resolution of a steroid-resistant, hypereosinophilic immune diathesis with mepolizumab and concomitant amelioration of a mixed thrombotic microangiopathy. Blood Cells Mol Dis. 2018;69:38-42.

Rosenbaum JN, Bloom R, Forys JT, Hiken J, Armstrong JR, Branson J, et al. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer. Mod Pathol. 2018;31(5):791-808.

Cheng S, Inghirami G, Cheng S, Tam W. Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL. J Hematol Oncol. 2018;11(1):105.